Cimidona

/ Rafa

1 tablet to be taken once daily, unchewed, with some fluid, preferably always at the same time of the day (in the morning or in the evening). The intake of the tablets does not depend on meals.
The effect does not set in immediately. Intake of the formulation is recommended for a period of at least 6 weeks.
It is recommended to take the drug over several months; however, it should not be applied for more than 6 months without medical advice.

For the alleviation of complaints during menopause (hot flashes, excessive perspiration, sleep disorders, nervousness and depressive moods).

Must not be taken in cases of existing hypersensitivity to one of its ingredients or to any plants of the Ranunculaceae (butter cup) family.

The intake of the formulation is not advised in cases of pre-existing liver damage. This preparation has an effect on physical and psychological complaints during the menopause. Since there is no clinical data so far with regard to a positive effect on bones, this preparation can therefore not be used for the prevention of osteoporosis.
Unusual fatigue, weakness or loss of appetite and unintended weight loss, yellow colouring of the conjunctiva or the skin, dark urine, or discolouration of stool can be an indication of liver damage. If such symptoms occur, the drug must be discontinued and a physician must be consulted.
A physician should be consulted in the event of a sensation of tension or swelling in the breasts or if irregular bleeding, spotting, or recurrence of menstrual bleeding occurs.
See prescribing information for full details.

Slight gastric complaints, nausea, severe liver damage, spotting and irregular bleeding as well as recurrence of menstrual bleeding can be observed in individual cases.
See prescribing information for full details.

None known.

The use of preparations containing Cimicifugae racemosae rhizoma is indicated for menopausal women. Administration during pregnancy and lactation is not intended.

No cases of overdose were reported.